Last Update

2016-05-08T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong ReGen Biologics?

ReGen Biologics

HQ Phone: (650) 562-0800

Email: r***@***.gov

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Ivy Sports Medicine LLC

102 Chestnut Ridge Rd Suite 204

Montvale, New Jersey 07645

United States

Company Description

Ivy Sports Medicine ("ISM") was formed in February of 2011 to create a global healthcare company focused on providing the best sports medicine therapies for orthopedic surgeons and patients. In June 2011, ISM acquired assets from ReGen Biologics out of Ch ... more

Find other employees at this company (15)

Background Information

Employment History

Senior Sales and Marketing Executive, Surgeon Training Underway

American Academy of Orthopaedic Surgeons

Sulzer Ltd

Director of Clinical Affairs

Howmedica Osteonics Corp

Affiliations

Board Member
Orthopedic Products Company

Adds New Board Member
PharmaLive

Adds New Board Member
Proteus Inc

Education

B.A.

biological science

Columbia College

Ph.D.

Web References (200 Total References)


Management Team | Ivy Sports Medicine

www.ivysportsmed.com [cached]

Before joining ReGen, he was Director of Clinical Affairs at Howmedica Osteonics, Inc. where he was responsible for the integration of the clinical departments of both companies after the acquisition by Stryker, Inc. Prior to that time, he worked for the Howmedica Division of Pfizer Medical Technology from 1984 to 1998 in a series of increasingly responsible positions in Research and Development and Regulatory Affairs. As Director of Regulatory Affairs and Public Policy, he was responsible for worldwide regulatory approvals for Howmedica's orthopaedic, craniomaxillofacial and neurological products. He holds a B.A. in biological science from Columbia College.


Before joining ReGen, ...

www.ivysportsmed.com [cached]

Before joining ReGen, he was Director of Clinical Affairs at Howmedica Osteonics, Inc. where he was responsible for the integration of the clinical departments of both companies after the acquisition by Stryker, Inc. Prior to that time, he worked for the Howmedica Division of Pfizer Medical Technology from 1984 to 1998 in a series of increasingly responsible positions in Research and Development and Regulatory Affairs. As Director of Regulatory Affairs and Public Policy, he was responsible for worldwide regulatory approvals for Howmedica's orthopaedic, craniomaxillofacial and neurological products. He holds a B.A. in biological science from Columbia College.

...
Mr. Bailey has worked in and run sales organizations focusing in Sports Medicine, Biologics, Joint Replacement and Spinal Implants.


Regen Biologics slams FDA for revoking Menaflex approval | OrthoSpineNews

www.orthospinenews.com [cached]

Regen Biologics slams FDA for revoking Menaflex approval | No comments Regen Biologics slams FDA for revoking Menaflex approval | OrthoSpineNews

...
Regen Biologics slams FDA for revoking Menaflex approval
...
Regen Biologics blasted the Food and Drug Administration Monday for its decision to revoke its 2-year-old approval of the company's leading product, a patch to repair the knee's meniscus tissue.
...
"Regen has invested 58 months and more than $30 million to meet (the center's) requirements," Bisbee stated, "only to have the agency reverse decisions made by previous officials by stating that they were in error with no substantial evidence that is true."


ReGen Biologics terminates ...

www.medcitynews.com [cached]

ReGen Biologics terminates stock after suing FDA ReGen Biologics terminates stock after suing FDA

...
ReGen Biologics terminates stock after suing FDA
ReGen Biologics Inc. (OTC:RGBO) terminated its common stock registration in connection with its bankruptcy proceedings connected to the FDA's rescission of 510(k) clearance for the company's Menaflex knee implant.
Earlier this month ReGen sued the FDA, its top regulator, and the secretary of the U.S. Department of Health & Human Services, accusing them of overstepping their bounds in rescinding the clearance.
...
That decision came the same week that the FDAreleased a report saying ReGen failed to produce adequate evidence that device was safe before it was cleared to hit the market.
...
ReGen Biologics terminates stock after suing FDA


ReGen Biologics terminates ...

www.medcitynews.com [cached]

ReGen Biologics terminates stock after suing FDA ReGen Biologics terminates stock after suing FDA

...
ReGen Biologics terminates stock after suing FDA
ReGen Biologics Inc. (OTC:RGBO) terminated its common stock registration in connection with its bankruptcy proceedings connected to the FDA's rescission of 510(k) clearance for the company's Menaflex knee implant.
Earlier this month ReGen sued the FDA, its top regulator, and the secretary of the U.S. Department of Health & Human Services, accusing them of overstepping their bounds in rescinding the clearance.
...
That decision came the same week that the FDAreleased a report saying ReGen failed to produce adequate evidence that device was safe before it was cleared to hit the market.
...
ReGen Biologics terminates stock after suing FDA

Similar Profiles

Other People with this Name

Other people with the name Biologics

MediVet Biologics
MediVet America LLC

ReGen Biologics
MiMecore Therapeutics LLC

Usp Biologics
U.S. Pharmacopeia

Scm Biologics
Dr. Reddy's Laboratories Ltd

Labrys Biologics

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory